Literature DB >> 17201886

Multiple viral hepatitis in injection drug users and associated risk factors.

Jens Reimer1, Juergen Lorenzen, Bernhard Baetz, Benedikt Fischer, Juergen Rehm, Christian Haasen, Markus Backmund.   

Abstract

BACKGROUND: While infections due to hepatitis B virus (HBV) and hepatitis C virus (HCV) have been well-studied in injection drug users (IDUs), hepatitis A virus (HAV) infection and coinfection with multiple hepatitis viruses have received less attention.
METHODS: Hepatitis serology as well as sociodemographic and drug-related parameters were explored in patients (n = 1512) admitted for opiate detoxification.
RESULTS: Antibodies to HAV were positive in 57.7%, to HBV in 53.0%, and to HCV in 75.0% of the sample. Lack of any hepatic marker was reported in 11.2%; one marker was positive in 24.7%; two markers were positive in 31.2%; and all markers were positive in 32.9%. In patients with one positive marker, 58.8% had had exposure to HCV, and 27% had exposure to HAV. In patients with two positive markers, 46.7% were HAV/HCV and 41.8% HBV/HCV antibody positive. Presence of HBV and HCV antibodies was associated with older age, longer duration of (i.v.) heroin use, and a higher number of rehabilitation treatment episodes (anova), current coconsumption of cocaine was associated with presence of antibodies to either HAV, HBV, and HCV.
CONCLUSIONS: Coinfection with hepatic viruses is highly relevant in IDUs, although HAV does not necessarily share the same risk factors relevant for HBV or HCV transmission. The need for outreach vaccination programs is emphasized for HAV and HBV in the target population. Primary prevention should be implemented before initiation or at early stages of a drug career. Epidemiology and transmission of HAV in IDUs requires further research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17201886     DOI: 10.1111/j.1440-1746.2006.04358.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  16 in total

1.  Multicentric evaluation of new commercial enzyme immunoassays for the detection of immunoglobulin M and total antibodies against hepatitis A virus.

Authors:  M C Arcangeletti; E Dussaix; F Ferraglia; A M Roque-Afonso; A Graube; C Chezzi
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

3.  Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy.

Authors:  M Rapicetta; R Monarca; L A Kondili; P Chionne; E Madonna; G Madeddu; A Soddu; A Candido; S Carbonara; M S Mura; G Starnini; S Babudieri
Journal:  Infection       Date:  2012-12-22       Impact factor: 3.553

4.  Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.

Authors:  M Serper; K A Forde; D E Kaplan
Journal:  J Viral Hepat       Date:  2017-09-21       Impact factor: 3.728

5.  Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis.

Authors:  Sandra E Larios; Carmen L Masson; Michael S Shopshire; Jennifer Hettema; Ashly E Jordan; Courtney McKnight; Christopher Young; Mandana Khalili; Randy M Seewald; Albert Min; Nicholas Hengl; James L Sorensen; Don C Des Jarlais; David C Perlman
Journal:  J Subst Abuse Treat       Date:  2013-11-11

6.  Occult hepatitis B virus infection among injecting drug users in the Central-West Region of Brazil.

Authors:  Márcia Alves Dias de Matos; Renata Carneiro Ferreira; Fabiana Perez Rodrigues; Tamíris Augusto Marinho; Carmen Luci Rodrigues Lopes; Antônia Carlos Magalhães Novais; Ana Rita Coimbra Motta-Castro; Sheila Araújo Teles; Francisco José Dutra Souto; Regina Maria Bringel Martins
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

7.  Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B.

Authors:  Gavin Bart; Paola Piccolo; Linqi Zhang; Ira Jacobson; Robert A Schaefer; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04       Impact factor: 6.526

8.  The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; Suzanne Brissette; Jill Chettiar; Pascal Schneeberger; David C Marsh; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  J Urban Health       Date:  2008-08-29       Impact factor: 3.671

9.  Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study.

Authors:  Ivar Skeie; Mette Brekke; Michael Gossop; Morten Lindbaek; Even Reinertsen; Magne Thoresen; Helge Waal
Journal:  BMJ Open       Date:  2011-08-06       Impact factor: 2.692

10.  Seroprevalence study of hepatitis C and Hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002-2006).

Authors:  Seyed Mohammad Alavi; Fatemeh Behdad
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.